O
BLUE

OrbiMed’s bluebird bio BLUE Stock Holding History

OrbiMed’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-29,892
Closed -$38.4M – 128
2018
Q4 		$38.4M Sell
29,892
-5,558
-16% -$8.53M 0.71% 46
2018
Q3 		$67M Sell
35,450
-2,239
-6% -$4.63M 0.81% 38
2018
Q2 		$76.6M Buy
37,689
+11,009
+41% +$25.1M 0.91% 37
2018
Q1 		$59M Sell
26,680
-2,968
-10% -$7.55M 0.73% 47
2017
Q4 		$68.4M Sell
29,648
-7,558
-20% -$15.3M 0.87% 38
2017
Q3 		$66.2M Buy
37,206
+6,341
+21% +$8.86M 0.63% 47
2017
Q2 		$42M Buy
30,865
+8,956
+41% +$10.8M 0.44% 62
2017
Q1 		$25.8M Hold
21,909
– – 0.29% 71
2016
Q4 		$17.5M Sell
21,909
-69,635
-76% -$55.3M 0.22% 72
2016
Q3 		$80.4M Hold
91,544
– – 0.92% 43
2016
Q2 		$51.3M Buy
91,544
+18,551
+25% +$10.5M 0.54% 50
2016
Q1 		$40.2M Buy
72,993
+294
+0.4% +$181K 0.42% 54
2015
Q4 		$60.5M Sell
72,699
-19,084
-21% -$19.1M 0.55% 50
2015
Q3 		$102M Buy
91,783
+17,802
+24% +$32.5M 1.03% 34
2015
Q2 		$161M Buy
73,981
+31,467
+74% +$64.1M 1.35% 25
2015
Q1 		$66.5M Buy
+42,514
New +$56.1M 0.57% 50
2014
Q2 		– Sell
-22,311
Closed -$6.57M – 135
2014
Q1 		$6.57M Buy
+22,311
New +$6.76M 0.08% 109
2013
Q4 		– Sell
-17,177
Closed -$6M – 123
2013
Q3 		$6M Buy
+17,177
New +$6.38M 0.11% 96

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's BLUE Position: Q1 2019 in Review

OrbiMed sold out of bluebird bio (BLUE) in Q1 2019, closing a stake of 29,892 shares — an estimated $38.4M sold.

OrbiMed first reported a position in BLUE in Q3 2013 and held it in 18 quarters. The position peaked at $161M in Q2 2015. 288 funds tracked by Wall St. Rank hold BLUE as of Q1 2019.

  • OrbiMed reported no remaining bluebird bio position as of Q1 2019 after selling out during the quarter.
  • OrbiMed sold 29,892 bluebird bio shares in Q1 2019, an estimated $38.4M.
  • OrbiMed first reported a position in bluebird bio in Q3 2013 and held it in 18 quarters.
  • OrbiMed's bluebird bio position peaked at $161M in Q2 2015.
  • 288 funds tracked by Wall St. Rank held bluebird bio as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.